Nantes, France – December 12, 2022, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the latest preclinical data on the use of its IL-7 receptor antagonist (IL-7R) , OSE-127, for the treatment of B- and T-cell precursor acute lymphoblastic leukemia (B- and -T-ALL) at the ASH (American Society of Hematolog y(1)) Annual Meeting on December 11, 2022 (New Orleans, Louisiana). This oral presentation received an “Abstract Achievement Award” from the peer review committee.